- Home
- IMNN vs GGRP Comparison
IMNN vs GGRP Comparison
Compare IMNN & GGRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$3.17
N/A
Current Price
$0.60
Company Overview
Basic Information| Metric | IMNN | GGRP |
|---|---|---|
| Founded | 1982 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0M | 12.5M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IMNN | GGRP |
|---|---|---|
| Price | $3.17 | $0.60 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $182.61 | N/A |
| AVG Volume (30 Days) | 22.6K | ★ 79.3K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $72.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.54 |
| 52 Week High | $9.32 | $0.64 |
Technical Indicators
Market Signals| Indicator | IMNN | GGRP |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 48.40 |
| Support Level | $3.03 | $0.55 |
| Resistance Level | $4.26 | $0.64 |
| Average True Range (ATR) | 0.22 | 0.05 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 27.36 | 49.50 |
Price Performance
Historical Comparison IMNN
GGRP
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).